Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Inclusion Criteria:

* Histologically or cytologically confirmed malignant melanoma and clinical evidence of metastatic disease to the brain. Mucosal and ocular melanomas are included.
* Newly developed inoperable brain metastases without associated hemorrhage or midline shift.
* Inoperable or metastatic extra cranial stage III or IV disease.
* Diagnostic quality MRI of the brain or if contraindicated then contrast CT scan of the head performed within 28 days prior to registration.
* Measurable metastases to the brain, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>10 mm in the brain MRI/CT scan.
* CT scan chest, abdomen and pelvis or PET CT scan performed within 28 days of study registration. For disease outside the brain, tumors must be \> 10 mm by CT scan.
* Prior therapy allowed but no prior therapy with nab-paclitaxel, paclitaxel, temozolomide, DTIC or bevacizumab.
* Bevacizumab may not be initiated until 4 weeks after surgical resection or radiation therapy completion.
* Age 18 or older.
* Pre-existing peripheral neuropathy must have \< Grade 2 (per CTCAE 4.0) at the time of registration.
* Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential.
* Women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment.
* ECOG Performance status 0-1.
* Estimated life expectancy of greater than 2 months.
* Patients must have adequate organ function as defined below (these must be evaluated within 14 days prior to registration):
* leukocytes \>3,000/mcL
* absolute neutrophil count \>1,500/mcL
* platelets \>100,000/mcL
* Hemoglobin \>9.0 g/dL
* AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit
* Alkaline phosphatase \<2.5 X institutional upper limit
* Total bilirubin \<1.5 X institutional upper limit of normal (unless associated with Gilbert's syndrome)
* serum creatinine \< 1.5 mg/dL OR 1.5 x institutional normal
* LDH there is no restriction
* INR \<1.5 PTT WNL
* Urine protein (UPC) ratio 1.0 OR
* Urine dipstick for proteinuria. Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
* Able to render informed consent.

Exclusion Criteria:

* Prior surgical resection for brain metastases.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab, nab-paclitaxel or temozolomide.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, unstable angina pectoris, untreated cardiac arrhythmia and peripheral vascular disease.
* History of myocardial infarction or unstable angina within 6 months prior to Day 1.
* History of stroke or transient ischemic attack within 6 months prior to Day 1.
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study screening.
* Serious, non-healed wound, ulcer, or bone fracture.
* History of hepatitis B, C or HIV.
* Uncontrolled hypertension or chronic renal disease. No known bleeding diathesis.
* Known hypersensitivity to human albumin.
* Surgery within 4 weeks of study registration. Must be fully recovered and fully healed from any prior surgery.
* Patients having chemotherapy or extra cranial radiotherapy within 4 weeks prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to the completion of study screening.
* Evidence of other concurrent active malignancy.
* Pregnant or nursing.
* Not be receiving any other investigational agent.